Publications by authors named "P A GALBRAITH"

Stormwater biofilters demonstrate promising treatment of faecal microorganisms, however performance can vary with design and operational conditions. This study investigated whether plants with significant documented antimicrobial activity could improve faecal bacterial treatment within biofilters. Laboratory-scale biofilters (n = 30) were dosed with synthetic stormwater containing faecal bacteria Escherichia coli, Enterococcus faecalis and Campylobacter jejuni under south-eastern Australian climatic conditions.

View Article and Find Full Text PDF

Bivalve growth is affected by phytoplankton quality and availability, but long-term, coastal environmental time series related to these parameters are often lacking. Therefore, it is crucial to develop methods to accurately quantify trends in phytoplankton dynamics over time. This would be especially important for the fished scallop beds in the northern Gulf of St.

View Article and Find Full Text PDF

Stormwater biofilters have demonstrated promising yet variable removal of faecal microorganisms. Significant antimicrobial-producing plants have been proposed as an inexpensive, safe and easily adaptable component of biofilter design to enhance faecal pathogen treatment. The aim of the present study was to investigate whether significant antimicrobial-producing plants improved faecal bacterial inactivation throughout the biofilter soil profile, focusing on four key treatment zones.

View Article and Find Full Text PDF

Background: Chronic total occlusions (CTO) occur in nearly 20% of coronary angiograms. CTO revascularization, either by percutaneous coronary intervention (PCI) or coronary artery bypass grafting surgery (CABG), is infrequently performed, approximately one-third of cases. Long-term outcomes are unknown.

View Article and Find Full Text PDF

Unlabelled: Older age has been shown to adversely impact overall survival (OS) in chronic lymphocytic leukemia (CLL) however, prior population-based studies did not analyze the impact of cytogenetic abnormalities or were prior to the availability of ibrutinib.

Objectives: i) We sought to compare outcomes of patients based on their age at treatment to examine if older age has an impact on OS in patients who were treated during the period when fludarabine-rituximab was the standard upfront therapy and when ibrutinib was first introduced and ii) compare outcomes based on whether the patient received primary treatment at an academic or community-based centre.

Methods: The BC Provincial CLL Database, a population-based databasewas used to include patients who have received treatment in British Columbia (BC), Canada between 2004 and 2016.

View Article and Find Full Text PDF